Uterine Cancer

P=N/A, N=600, Not yet recruiting, Asan Medical Center

Nicotinamide metabolism was found to be significantly linked with EC progression. This study offers new perceptions into the role of nicotinamide metabolism in EC and suggests possible avenues for treatment advancements.

In this context, the CAP regimen-comprising cyclophosphamide, adriamycin, and cisplatin-has demonstrated superior overall efficacy. Moreover, these tumors seem to be relatively resistant to radiation therapy.

Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy was performed uneventfully, and at 7 months she remains disease-free. The case underlines that adenosarcoma can masquerade as cervical cancer, emphasises the need for generous tissue sampling and WT1/ER-based immunohistochemistry to define tumour origin, and confirms excellent outcomes with complete surgical excision for stage I disease.

P=N/A, N=134, Not yet recruiting, Xuzhou Central Hospital; Xuzhou Central Hospital

P=N/A, N=316, Completed, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

The patient remains disease-free at 4 months. This case expands the molecular spectrum of ELMS and, concomitantly, broadens the emerging morphologic spectrum of RAD51B-rearranged uterine sarcomas, underscoring the diagnostic value of fusion testing in unusual uterine mesenchymal neoplasms.

A coordinated mechanism where uterine cancer cells adaptively up-regulate RFVTs, FADS, and LSD1 to meet their metabolic demands was revealed. These results provide insights into the metabolic vulnerabilities of uterine cancer and propose Rf metabolism and flavin-dependent processes as potential therapeutic targets.

DEHP-THRB showed strongest binding affinity, suggesting direct toxicological interaction. This study characterizes a computationally derived gene signature associated with DEHP toxicity in UCEC, highlighting their prognostic and immunological significance as potential molecular footprints, while acknowledging that direct exposure inference requires future validation with measured biomonitoring data.

We also discuss investigational drugs that hold promise for the theranostic treatment of persistent, recurrent, or metastatic uterine cervical cancer, including inhibitors of fibroblast activation protein-alpha and ribonucleotide reductase. In our expert opinion, the development of a theranostic radiopharmaceutical should pursue the eventual goal of being tested in a randomized phase II monotherapy setting.

P=N/A, N=23, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Moreover, the results of our study suggest that tumors with CTNNB1 mutation and GREB1::CTNNB1 fusion may exhibit identical morphology and potentially represent the same category of tumor. Characterization and reporting of additional cases are needed to determine whether these are part of the spectrum of low-grade endometrial stromal tumors (either endometrial stromal nodule or LGESS) or represent a separate category of tumors characterized by CTNNB1 alteration as a driver event.